capecitabine has been researched along with Cystitis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bajetta, E; Biondani, P; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Formisano, B; Gevorgyan, A; Grassi, P; Mariani, L; Pietrantonio, F; Valvo, F | 1 |
Agolli, L; Borro, M; Bracci, S; De Sanctis, V; Di Nardo, F; Enrici, RM; Falco, T; Gentile, G; Maglio, M; Minniti, G; Nicosia, L; Osti, MF; Simmaco, M; Valeriani, M | 1 |
1 trial(s) available for capecitabine and Cystitis
Article | Year |
---|---|
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cystitis; Deoxycytidine; Diarrhea; Digestive System Surgical Procedures; Drug Chronotherapy; Feasibility Studies; Female; Fluorouracil; Humans; Leukopenia; Male; Middle Aged; Oxaloacetates; Proctitis; Rectal Neoplasms; Severity of Illness Index; Treatment Outcome | 2014 |
1 other study(ies) available for capecitabine and Cystitis
Article | Year |
---|---|
Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cystitis; Diarrhea; DNA-Binding Proteins; Female; Fluorouracil; Gastrointestinal Hemorrhage; Genotype; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pelvic Pain; Polymorphism, Single Nucleotide; Proctitis; Rad51 Recombinase; Radiation Injuries; Radiodermatitis; Radiotherapy, Conformal; Rectal Neoplasms; X-ray Repair Cross Complementing Protein 1 | 2017 |